Table 1.
Comparison of clinical features between S-IPF and AE-IPF patients.
| Clinical variables | S-IPF group | AE-IPF group | p-value |
|---|---|---|---|
| Population demography | |||
| Gender (M/F) | 49/12 | 37/10 | 0.837 |
| Age (years) | 67.0 ± 8.3 | 68.5 ± 7.2 | 0.308 |
| Smoking (pack*years) | 16.8 ± 21.5 | 16.9 ± 22.0 | 0.971 |
| Inflammation and infection | |||
| Concurrent infection | 9/52 | 26/21 | <0.001 |
| Prior corticosteroid use (Y/N) | 27/34 | 35/12 | 0.002 |
| Fever (Y/N) | 3/58 | 19/28 | <0.001 |
| CD4+ lymphocyte counts (×109) | 0.703 ± 0.281 | 0.352 ± 0.302 | <0.001 |
| WBC counts (×109) | 6.50 (2.6-11.3) | 10 (2.7-20.1) | <0.001 |
| CRP (mg/L) | 3.50 (1.0-126.5) | 17.5 (1.0-442.6) | <0.001 |
| ESR (mm/h) | 15 (0-84) | 38 (2-94) | <0.001 |
| LDH (U/L) | 231 (166-407) | 389 (181-1267) | <0.001 |
| Metabolism | |||
| TG (mmol/L) | 1.56 ± 1.12 | 1.09 ± 0.85 | 0.008 |
| Apo AI (g/L) | 1.10 ± 0.30 | 0.97 ± 0.28 | 0.023 |
| AIB (g/L) | 39.36 ± 4.09 | 33.13 ± 5.58 | <0.001 |
| GLU (mmol/L) | 4.86 (3.53-13.84) | 5.83 (2.03-17.67) | <0.001 |
| Disease severity | |||
| PaO2/FiO2 ratio | 357 (224-476) | 195 (49.0-496.0) | <0.001 |
| D-dimer (mg/L) | 0.35 (0.11-2.52) | 1.05 (0.21-28.96) | <0.001 |
| HRCT Score | 3.45 ± 1.27 | 6.57 ± 1.16 | <0.001 |
| PAH (<40/≥40 mmHg) | 44/4 | 14/18 | <0.001 |
| FVC (L) | 2.33 ± 0.83 (59) | 1.76 ± 0.53 (34) | 0.001 |
| DLCO % pred | 55.95 ± 20.08 (54) | 34.92 ± 19.53 (25) | <0.001 |
| GAP scores | 3.71 ± 1.67 | 5.39 ± 1.71 | <0.001 |
| GAP stage (I/II/III) | 28/22/8 | 5/11/17 | <0.001 |